Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Orange, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Riverside, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Santa Ana, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Torrance, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Walnut Creek, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Aurora, CO
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Boca Raton, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Jupiter, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Jupiter, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Miami, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Orlando, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Trinity, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Trinity, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Winter Park, FL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Winter Park, FL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Atlanta, GA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Honolulu, HI
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Boise, ID
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Boise, ID
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Idaho Falls, ID
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Chicago, IL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Baltimore, KA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Baltimore, KA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Topeka, KA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Baltimore, MD
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Worcester, MA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Worcester, MA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Detroit, MI
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Kalamazoo, MI
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Gulfport, MS
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Gulfport, MS
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Columbia, MO
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Columbia, MO
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Kansas City, MO
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Omaha, NE
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Neptune City, NJ
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Neptune City, NJ
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Buffalo, NY
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Mineola, NY
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
New York, NY
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Rochester, NY
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Durham, NC
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Columbus, OH
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Dayton, OH
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Mentor, OH
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Mentor, OH
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Tulsa, OK
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Eugene, OR
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Eugene, OR
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Portland, OR
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Langhorne, PA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Langhorne, PA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Charleston, SC
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Rapid City, SD
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Memphis, TN
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials